Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

rter culminated with the FDA approval of DIFICID for the treatment of C. difficile-associated diarrhea, or CDAD, in patients over the age of 18, which includes clear differentiation and superiority over oral vancomycin in sustained clinical response 25 days after the end of therapy," said Pedro Lichtinger, President and CEO of Optimer.  "Our success with the FDA approval and the recent launch of DIFICID can be attributed to thorough preparation and execution by our team. We remain highly focused on the successful introduction of DIFICID to physicians and patients, and on establishing DIFICID, based on the clinical experience to date, as the preferred treatment for CDAD patients."

Second Quarter and Recent Highlights

  • On May 27, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID™ (fidaxomicin) Tablets for the treatment of CDAD in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease.
  • On July 18, Optimer announced the commercial launch of DIFICID™ Tablets for the treatment of CDAD in patients 18 years of age and older.
  • Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID for the treatment of CDAD in the U.S. to help maximize the impact of, and de-risk, the commercial launch of DIFICID.
  • Optimer also presented additional data analysis from the DIFICID Phase 3 clinical trials highlighting risk factors associated with negative outcomes in patients with CDAD such as advanced age and immunosuppression. Data were presented at key scientific conferences including the European Congress of Clinical Microbiology and Infectious Diseases, Digestive Disease Week and the Annual Meeting of the American Geriatric Society.

  • About Op
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
    2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
    4. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
    5. Optimer Pharmaceuticals Expands Senior Management Team
    6. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
    7. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
    8. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
    9. Trading Halted Today in Optimer Pharmaceuticals Stock
    10. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
    11. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
    (Date:7/30/2014)... Germany , July 30, 2014  invendo medical ... computer-assisted ("robotic") colonoscopy system, today announced the appointment of ... device executive, as a new member of its supervisory ... respected global visionary in the medical device industry. In ... Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: GIVN), ...
    (Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
    Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
    ... LIUZHOU CITY, China , July 19 ... CNBI), ("China BCT" or the,"Company"), a leading pharmaceutical distributor, ... Province , China , today,announced that on ... Public,Accountants, A Professional Corporation, Glendale, California ("PKF,California"), ...
    ... 19 "This is a historic day for HIV prevention research. ... gel can help to prevent sexual transmission of HIV infection," said AVAC ... landmark microbicide trial presented today at the International AIDS Conference in ... "We believe ...
    Cached Medicine Technology:China BCT Announces Auditor Change Within PKF Network 2China BCT Announces Auditor Change Within PKF Network 3AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides 2AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides 3AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides 4
    (Date:7/30/2014)... Colorado (PRWEB) July 30, 2014 Daily Gossip ... attacks can occur easily. A panic attack is a feeling ... various factors. There are a series of symptoms that sufferers ... This includes shortness of breath, stress or anxiety. Naturally, panic ... fast and effective way to overcome them. , The 60 ...
    (Date:7/30/2014)... MyMobileUniversity (MMU) is a global initiative ... award winning mobile and web based learning company that ... , MyMobileUni.com’s platform makes it a one-stop centre to ... links to the world’s leading Massive Open Online Courses ... from all over the world who have content that ...
    (Date:7/30/2014)... July 30, 2014 Nationally recognized leader ... ANEF, who since September 2013 has served as president ... the new dean of the College of Nursing at ... marries her leadership of the NLN, as the nation's ... top-ranked academic nursing and research institutions in the country. ...
    (Date:7/30/2014)... July 30, 2014 Within weeks freshman will begin ... promise. Each hopes this will be a time of growth and ... each to pause; it may not be as easy as it ... students will switch their major at least once and many will ... energy and the costs are exacerbated when switching in the later ...
    (Date:7/30/2014)... Throughout the month of August, Restore ... cancer screenings. Using a new technological tool called The ... disease in its early stages. , Oral cancer can ... throat and other areas in and around the mouth. ... Ends Results (SEER) program, 30 percent of oral cancers ...
    Breaking Medicine News(10 mins):Health News:60 Second Panic Solution Review Reveals Unique Way to Stop Panic Attacks 2Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 2Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 3Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2
    ... all over the world gathered at the Gibson Hall ... Journal (GCPj) Awards. Opening,this landmark event, Chairman of the ... awards were a most important celebration,of innovation and enterprise ... become a traditional event in the public health calendar", ...
    ... For the first time,high definition (HD) video footage of ... and fertility specialist at Syosset and North Shore,University hospitals, ... 16 on the National Geographic Channel in stories that ... body. Dr. Palter is internationally recognized for his ...
    ... WASHINGTON, Sept. 7 The Sudden Cardiac Arrest,Association (SCAA) ... "We are excited to have Chris join SCAA as ... membership base, and work toward our goal of,eliminating preventable ... Richard Brown, chair of the SCAA Board of Directors.,"Advancements ...
    ... of Military and Veterans Affairs today dedicated a ... and,Sailors, Home., "With the completion of this ... for Pennsylvania,s 1.1 million veterans who,have served so ... Gen.,Jessica L. Wright, state adjutant general. "Now, all ...
    ... those with no asthma history, study finds , FRIDAY, Sept. ... have what,s known as exercise-induced asthma, even though they may ... shows. , Previous research in Olympic athletes has also shown ... in this study, because many of the reported severe episodes ...
    ... with Heparin Bioactive Surface Offers Safe, ... Effective Alternative to Surgery, ... Hospital became the world,s first physician on Wednesday, Aug.,29, to ... a new,device that improves outcomes, speeds recovery and may minimize ...
    Cached Medicine News:Health News:Good Clinical Practice Journal Awards: Winners Announced 2Health News:Good Clinical Practice Journal Awards: Winners Announced 3Health News:Good Clinical Practice Journal Awards: Winners Announced 4Health News:Revolutionary HD Surgical Footage from North Shore-LIJ Surgeon to be Broadcast for the First Time on ABC's 20/20, National Geographic Channel 2Health News:Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association 2Health News:1 in 3 Varsity Athletes Has Exercise-Induced Asthma 2Health News:Riverside First to Offer New Treatment for Peripheral Arterial Disease 2Health News:Riverside First to Offer New Treatment for Peripheral Arterial Disease 3
    InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
    The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
    The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
    D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
    Medicine Products: